Listed by the USPTO as LUNDE, GRACE HENRY
Tech Center 1600 • Art Units: 1641 1643
This examiner grants 63% of resolved cases
LUNDE, GRACE HENRY is assigned to tech center 1600 and art unit 1641. The record contains 27 resolved cases, a 63.0% allowance rate, and a 1338-day median time to allowance. Interviews correspond to a 38.9% lift in the allowance outcome.
The limited resolved-case volume makes the measures useful as a focused signal rather than a broad historical record. Within that record, allowance occurs in more than half of the matters, and the interview measure is substantial. Counsel may consider interviews when developing a response strategy, while treating the sample size as an important qualification. The main companies are UMC Utrecht Holding B.V., H. Lee Moffitt Cancer Center and Research Institute Inc., and Yeda Research and Development Co. Ltd.
The main firms are Fox Rothschild LLP, Ipsilon USA - NLO, and MAIER & MAIER, PLLC. These organizations provide the principal representation context.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18058707 | CHIMERIC ANTIGEN RECEPTORS BASED ON ALTERNATIVE SIGNAL 1 DOMAINS | Final Rejection | The General Hospital Corporation |
| 17908545 | Membrane Ubiquitin ligases to target protein degradation | Non-Final OA | UMC Utrecht Holding B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.0% of resolved applications examined by Grace Henry Lunde were allowed (27 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +38.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Grace Henry Lunde took 1,338 days on average from filing to allowance.
Grace Henry Lunde examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
